These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 17332339)

  • 1. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
    Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ
    Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
    Qian J; Niu J; Li M; Chiao PJ; Tsao MS
    Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells.
    Ulkü AS; Schäfer R; Der CJ
    Mol Cancer Res; 2003 Dec; 1(14):1077-88. PubMed ID: 14707291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling.
    Repasky GA; Zhou Y; Morita S; Der CJ
    Mol Carcinog; 2007 Dec; 46(12):958-70. PubMed ID: 17477350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells.
    Hayes CS; DeFeo K; Lan L; Paul B; Sell C; Gilmour SK
    Oncogene; 2006 Mar; 25(10):1543-53. PubMed ID: 16278677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K; Park S; Ewton DZ; Friedman E
    Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
    Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
    Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Ras transformation of human thyroid epithelial cells.
    Poghosyan Z; Wynford-Thomas D
    Methods Enzymol; 2006; 407():648-60. PubMed ID: 16757359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells.
    Agbunag C; Bar-Sagi D
    Cancer Res; 2004 Aug; 64(16):5659-63. PubMed ID: 15313904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38.
    Dreissigacker U; Mueller MS; Unger M; Siegert P; Genze F; Gierschik P; Giehl K
    Cell Signal; 2006 Aug; 18(8):1156-68. PubMed ID: 16257181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-Ras promotes tumor growth of cervical epithelial cells.
    Rincón-Arano H; Rosales R; Mora N; Rodriguez-Castañeda A; Rosales C
    Cancer; 2003 Feb; 97(3):575-85. PubMed ID: 12548599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration.
    Giehl K; Skripczynski B; Mansard A; Menke A; Gierschik P
    Oncogene; 2000 Jun; 19(25):2930-42. PubMed ID: 10871844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PKC Delta (PKCdelta) promotes tumoral progression of human ductal pancreatic cancer.
    Mauro LV; Grossoni VC; Urtreger AJ; Yang C; Colombo LL; Morandi A; Pallotta MG; Kazanietz MG; Bal de Kier Joffé ED; Puricelli LL
    Pancreas; 2010 Jan; 39(1):e31-41. PubMed ID: 19924022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.
    Lim KH; O'Hayer K; Adam SJ; Kendall SD; Campbell PM; Der CJ; Counter CM
    Curr Biol; 2006 Dec; 16(24):2385-94. PubMed ID: 17174914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling.
    Lee SG; Su ZZ; Emdad L; Sarkar D; Franke TF; Fisher PB
    Oncogene; 2008 Feb; 27(8):1114-21. PubMed ID: 17704808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
    Brembeck FH; Schreiber FS; Deramaudt TB; Craig L; Rhoades B; Swain G; Grippo P; Stoffers DA; Silberg DG; Rustgi AK
    Cancer Res; 2003 May; 63(9):2005-9. PubMed ID: 12727809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
    Du J; Jiang B; Coffey RJ; Barnard J
    Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Raf-1 in human pancreatic adenocarcinoma.
    Berger DH; Jardines LA; Chang H; Ruggeri B
    J Surg Res; 1997 Apr; 69(1):199-204. PubMed ID: 9202670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.